Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

RATIONALE & OBJECTIVE: The approved therapeutic indication for immune checkpoint inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the immune related toxicities associated with CPI can limit the efficacy of these agents. The literature on the nephrotoxicity of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Mamlouk, Omar, Selamet, Umut, Machado, Shana, Abdelrahim, Maen, Glass, William F., Tchakarov, Amanda, Gaber, Lillian, Lahoti, Amit, Workeneh, Biruh, Chen, Sheldon, Lin, Jamie, Abdel-Wahab, Noha, Tayar, Jean, Lu, Huifang, Suarez-Almazor, Maria, Tannir, Nizar, Yee, Cassian, Diab, Adi, Abudayyeh, Ala
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Short Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6322290/
https://ncbi.nlm.nih.gov/pubmed/30612580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0478-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi